View More Recent Stories

Sep 23, 2024 08:17AM SciSparc (SPRC) Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
Sep 18, 2024 04:09PM SciSparc (SPRC) Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
Sep 16, 2024 04:06PM Clearmind Medicine (CMND) Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
Sep 11, 2024 07:40AM SciSparc (SPRC) Advances $1.85M Loan to AutoMax
Sep 6, 2024 07:56AM Clearmind Medicine (CMND) Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Aug 29, 2024 04:26PM Clearmind Medicine (CMND) Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Aug 28, 2024 08:55AM SciSparc (SPRC) Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
Aug 22, 2024 08:16AM SciSparc (SPRC): MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
Aug 19, 2024 04:11PM SciSparc (SPRC) Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
Aug 14, 2024 04:54PM SciSparc (SPRC) Issues Update Regarding the Status of the AutoMax Merger
Aug 6, 2024 08:58AM SciSparc (SPRC) and Clearmind Medicine (CNMD) Announce New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
Jul 17, 2024 07:07AM SciSparc (SPRC) Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
Jul 16, 2024 11:55AM SciSparc (SPRC) Announces Receipt of Nasdaq Minimum Bid Price Notification
Jul 16, 2024 06:03AM SciSparc (SPRC) Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
Jul 8, 2024 08:30AM SciSparc (SPRC) Enters Non-binding LoI for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio
View More Recent Stories